Combined metabolic activators improve cognitive functions in Alzheimer ’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
ConclusionOur results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.Trial registration ClinicalTrials.gov NCT04044131 Registered 17 July 2019,https://clinicaltrials.gov/ct2/show/NCT04044131
Source: Translational Neurodegeneration - Category: Neurology Source Type: research
More News: Acetylcysteine | Alzheimer's | Brain | Clinical Trials | Mitochondria | Neurology | Study | Vitamin B3